| A | B | C | D | E | F | G | H | I | J | K | L | M | N | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ||||||||||||||
| 2 | Brand | Indication | Economics | Phase | Price KRW | 820000 | ||||||||
| 3 | Byooviz (ranibizumab, fka SB11) | Shares | 71.174 | |||||||||||
| 4 | trastuzumab (fka SB3) | MC KRW | 58362.68000000001 | |||||||||||
| 5 | etanercept (fka SB4) | Cash KRW | 3099.8 | Q322 | ||||||||||
| 6 | infliximab (fka SB2) | Debt KRW | 2078.4 | Q322 | ||||||||||
| 7 | bevacizumab (fka SB8) | EV KRW | 57341.280000000006 | |||||||||||
| 8 | adalimumab (fka SB5) | |||||||||||||
| 9 | ||||||||||||||
| 10 | SB15 (aflibercept) | |||||||||||||
| 11 | SB17 (ustekinumab) | |||||||||||||
| 12 | SB12 (eculizumab) | |||||||||||||
| 13 | SB16 (denosumab) | Osteoporosis |